PMID- 16144920
OWN - NLM
STAT- MEDLINE
DCOM- 20051101
LR  - 20220330
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 11
IP  - 17
DP  - 2005 Sep 1
TI  - Hepatocyte growth factor promotes cancer cell migration and angiogenic factors 
      expression: a prognostic marker of human esophageal squamous cell carcinomas.
PG  - 6190-7
AB  - PURPOSE: Hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, 
      c-Met, play important roles in tumor development and progression. In this study, 
      we measured the serum HGF levels in patients with esophageal squamous cell 
      carcinoma (ESCC) to evaluate its relationships with clinicopathologic features 
      and the role of HGF in ESCC. EXPERIMENTAL DESIGN: One hundred and forty-nine 
      patients with ESCC were studied. Pretherapy serum was collected and ELISA was 
      used to detect the concentrations of HGF, vascular endothelial growth factor 
      (VEGF), and interleukin 8 (IL-8). The function of HGF was shown by invasion 
      chamber assay. RESULTS: Pretherapy serum HGF was found to be significantly higher 
      in patients with ESCC than in control subjects. The levels of HGF correlated 
      significantly with advanced tumor metastasis stage and survival. Multivariate 
      analyses showed that serum HGF level in cell migration was an independent 
      prognostic factor. Increased HGF serum levels correlated positively with serum 
      levels of VEGF and IL-8. Our results also showed that HGF was overexpressed in 
      ESCC tissues and cell lines. In vitro study showed that HGF could stimulate ESCC 
      cell to express VEGF and IL-8 and markedly enhance invasion and migration of ESCC 
      cells. Furthermore, HGF-induced IL-8 and VEGF expression was dependent on 
      extracellular signal-regulated kinase signaling pathways. The inhibition of 
      extracellular signal-regulated kinase activation reduced HGF-mediated IL-8 and 
      VEGF expression. CONCLUSIONS: Our results suggest that serum HGF may be a useful 
      biomarker of tumor progression and a valuable independent prognostic factor in 
      patients with ESCC. HGF may be involved in the progression of ESCC as an 
      autocrine/paracrine factor via enhancing angiogenesis and tumor cell invasion and 
      migration.
FAU - Ren, Yi
AU  - Ren Y
AD  - Department of Surgery, University of Hong Kong Medical Centre, Queen Mary 
      Hospital, Hong Kong, PR China. slaw@hku.hk
FAU - Cao, Brian
AU  - Cao B
FAU - Law, Simon
AU  - Law S
FAU - Xie, Yi
AU  - Xie Y
FAU - Lee, Ping Yin
AU  - Lee PY
FAU - Cheung, Leo
AU  - Cheung L
FAU - Chen, Yongxong
AU  - Chen Y
FAU - Huang, Xin
AU  - Huang X
FAU - Chan, Hiu Man
AU  - Chan HM
FAU - Zhao, Ping
AU  - Zhao P
FAU - Luk, John
AU  - Luk J
FAU - Vande Woude, George
AU  - Vande Woude G
FAU - Wong, John
AU  - Wong J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Interleukin-8)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoma, Squamous Cell/*blood/diagnosis
MH  - Cell Movement/*physiology
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Esophageal Neoplasms/*blood/diagnosis
MH  - Esophagus/metabolism
MH  - Female
MH  - Hepatocyte Growth Factor/*blood
MH  - Humans
MH  - Interleukin-8/*blood
MH  - MAP Kinase Signaling System
MH  - Male
MH  - Neovascularization, Pathologic
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-met/metabolism
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2005/09/08 09:00
MHDA- 2005/11/03 09:00
CRDT- 2005/09/08 09:00
PHST- 2005/09/08 09:00 [pubmed]
PHST- 2005/11/03 09:00 [medline]
PHST- 2005/09/08 09:00 [entrez]
AID - 11/17/6190 [pii]
AID - 10.1158/1078-0432.CCR-04-2553 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2005 Sep 1;11(17):6190-7. doi: 10.1158/1078-0432.CCR-04-2553.